Clinical Field Study
Study results demonstrated a significantly higher proportion of inappetent dogs that received ENTYCE® (capromorelin oral solution) had an increase in appetite compared to dogs that received placebo in a large population of client-owned dogs with reduced appetite of varying etiologies.1
View study design
- Blinded, placebo-controlled, multi-site study
- 244 client-owned dogs enrolled, 2:1 randomization
- Inappetence from a variety of causes
- 3 mg/kg once daily oral liquid for 4 days
- All dogs enrolled in the study were evaluated for adverse reactions throughout the course of the study
Primary Endpoint: Owner Appetite Assessment
- Success Rate on day 4
|Treatment success–single-question assessment %*||68.6||44.6||0.0078|
|Treatment success–Owner Appetite Assessment, %**||56.2||26.8||0.0071|
|Percent change in Owner Appetite Assessment, mean (±SD)||73.3 (±75.9)||37.6 (±53.9)||0.0125|
|Percent change in body weight, mean (±SD)||1.83 (±2.75)||0.11 (±3.61)||0.0004|
*A dog was considered a treatment success if the owner answered that their dog’s appetite was increased in response to the question, “Do you feel that during the study (over the 4 ± 1 days of treatment) your dog’s appetite was increased, no change or decreased?”
**Treatment success was defined as an increase in total score ? 5 from day 0 to day 3 ± 1 (scoring scale 5-25)
Laboratory Effectiveness Study
The results of this study in healthy beagle dogs demonstrated a significant increase in mean (SD) food consumption for dogs treated with ENTYCE® (capromorelin oral solution) compared to dogs that received placebo over four days of treatment.2
View study design
- Randomized, masked, placebo-controlled study
- 24 lab beagle dogs enrolled; 1:1 randomization
- 3 mg/kg once-daily oral liquid for 4 days
- Dogs observed for clinical signs throughout course of study
- Physical exams completed prior to and end of treatment
- Blood drawn before and after treatment for evaluation of serum chemistry and hematology parameters
|Food consumption and body weight changes in dogs treated with either placebo or capromorelin|
|Percent food consumption change (Mean ± SD)||Percent weight Increase from day 0 to day 3 (Mean ± SD)|
|Capromorelin||60.55 ± 39.87a||5.96 +1.76|
|Placebo||-11.15 ± 14.23b||0.053 + 1.14|
Dogs (n=6 males and 6 females per group) were treated 4 days with either placebo or 3 mg/kg/day ENTYCE oral solution.
aMean increase of 117.6 grams of food daily.
bMean decrease of 30.4 grams of food daily.
1Zollers B, Wofford JA, Heinen E, Huebner M, Rhodes L. A Prospective, Randomized, Masked, Placebo-Controlled Clinical Study of Capromorelin in Dogs with Reduced Appetite. J Vet Intern Med. 2016;30(6):1851-1857.
2Zollers B, Rhodes L, Heinen E. Capromorelin oral solution (ENTYCE®) increases food consumption and body weight when administered for 4 consecutive days to healthy adult Beagle dogs in a randomized, masked, placebo controlled study. BMC Vet Res. 2017; 13:10.
IMPORTANT SAFETY INFORMATION: ENTYCE® (capromorelin oral solution) is for use in dogs only. Do not use in breeding, pregnant or lactating dogs. Use with caution in dogs with hepatic dysfunction or renal insufficiency. Adverse reactions in dogs may include diarrhea, vomiting, polydipsia, and hypersalivation. Should not be used in dogs that have a hypersensitivity to capromorelin. Please see the full Prescribing Information for more detail.
Other therapeutics from Aratana
NOCITA® (bupivacaine liposome injectable suspension) is the only long-acting local anesthetic that controls cranial cruciate ligament (CCL) post-op pain with one dose for up to 72 hours.
You can be sure that the local relief will help keep your patient is comfortable even after going home.
IMPORTANT SAFETY INFORMATION: NOCITA® (bupivacaine liposome injectable suspension) is for use in dogs only. Do not use in dogs younger than 5 months of age, dogs used for breeding, or in pregnant or lactating dogs. Do not administer by intravenous or intra-arterial injection. Adverse reactions in dogs may include discharge from incision, incisional inflammation and vomiting. Avoid concurrent use with bupivacaine HCl, lidocaine or other amide local anesthetics. Please see the full Prescribing Information for more detail.